Research and Development

Showing 15 posts of 9596 posts found.

Alnylam shares positive results from phase 1 trial

July 17, 2023 Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …

Recursion and NVIDIA partner for AI-enabled drug discovery developments

July 13, 2023 Research and Development AI, Pharmacy, Recursion, drug discovery

Clinical stage biotech company Recursion has announced a $50m investment by NVIDIA, intended to accelerate the development of its AI …
needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023 Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial

July 11, 2023 Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma

Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …
eye2

Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023 Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …

OSE Immunotherapiesโ€™ UC drug gets DSMB positive recommendation

July 6, 2023 Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis

Frenchย biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trialโ€™s Independent Drug Safety Monitoring Board (DSMB) has provided …

FDA grants Priority Review for Astellas Pharmaโ€™s BLA for cancer drug

July 6, 2023 Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology

Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …

Skyline Therapeutics receives FDA clearance of IND for candidate for neovascular age-related macular degeneration

July 5, 2023 Research and Development FDA, IND, Opthalmology, Skyline Therapeutics, neovascular age-related macular degeneration

Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …

Amsterdam UMCโ€™s new drug doubles remission rates in patients with ulcerative colitis

July 4, 2023 Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis

A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …
brainss

Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023 Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTLโ€™149), a …

Astellas establishes open innovation hub for tumour microenvironment research

June 29, 2023 Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …

Anavex Life Sciences and Partex NV Group announce AI-based strategic partnership to enhance patient experience

June 28, 2023 Research and Development AI, Anavex Life Sciences, Partex NV Group, Pharmacy, patient experience

US-based clinical-stage biopharmaceutical company Anavex Life Sciences and German digital pharma platform Partex NV Group have announced a strategic partnership …
markus-spiske-dnbtfbnqlrc-unsplash_1

GSK receives FDA Fast Track designation for novel gonorrhoea vaccine

June 27, 2023 Research and Development FDA, GSK, Infections and infestations, Vaccine, fast track designation, gonorrhoea

GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational vaccine …
lungs

Verona Pharma submits FDA New Drug Application for COPD treatment

June 27, 2023 Research and Development COPD, Cardiology, FDA, ensifentrine, new drug application, verona pharma

UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug …
blood-1813410_960_720

Sanofi shares data about new drug for haemophilia A in paediatric patients

June 26, 2023 Research and Development Haematology, Sanofi, clinical trial, haemophilia a

Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …
The Gateway to Local Adoption Series

Latest content